ChemicalBook >> CAS DataBase List >>Exemestane

Exemestane

CAS No.
107868-30-4
Chemical Name:
Exemestane
Synonyms
AROMASIN;EXALAMIDE;Exemestan;ExeMestane(AroMasin);EXE;ROMASIN;PNU155971;FCE-24304;ExeMestine;Exemestone
CBNumber:
CB5760314
Molecular Formula:
C20H24O2
Molecular Weight:
296.4
MDL Number:
MFCD00866994
MOL File:
107868-30-4.mol
Modify Date:2023-03-29 12:04:30

Exemestane Properties

Melting point 155.13°C
Boiling point 453.7±45.0 °C(Predicted)
Density 1.13±0.1 g/cm3(Predicted)
storage temp. 2-8°C
solubility DMSO: ≥20mg/mL
form powder
color white to off-white
optical activity [α]/D +250 to +300°, c = 1 in methanol
InChI InChI=1S/C20H24O2/c1-12-10-14-15-4-5-18(22)20(15,3)9-7-16(14)19(2)8-6-13(21)11-17(12)19/h6,8,11,14-16H,1,4-5,7,9-10H2,2-3H3/t14-,15-,16-,19+,20-/m0/s1
InChIKey BFYIZQONLCFLEV-DAELLWKTSA-N
SMILES C1(=O)C=C2[C@](C)(C=C1)[C@]1([H])[C@]([H])([C@@]3([H])[C@@](CC1)(C)C(=O)CC3)CC2=C
CAS DataBase Reference 107868-30-4(CAS DataBase Reference)
FDA UNII NY22HMQ4BX
NCI Dictionary of Cancer Terms Aromasin; exemestane
NCI Drug Dictionary Aromasin
ATC code L02BG06

Pharmacokinetic data

Protein binding 90%
Excreted unchanged in urine <1%
Volume of distribution 20 000 Litres
Biological half-life 24 / -

SAFETY

Risk and Safety Statements

Symbol(GHS)  GHS hazard pictogramsGHS hazard pictograms
GHS08,GHS09
Signal word  Danger
Hazard statements  H360-H411
Precautionary statements  P201-P202-P273-P280-P308+P313-P391
Hazard Codes  T,N
Risk Statements  60-61-51
Safety Statements  53-22-36/37-57
WGK Germany  3
HS Code  29372900

Exemestane price More Price(29)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Sigma-Aldrich PHR1634 Exemestane Pharmaceutical Secondary Standard; Certified Reference Material 107868-30-4 1g $112 2022-05-15 Buy
Sigma-Aldrich 1269050 Exemestane United States Pharmacopeia (USP) Reference Standard 107868-30-4 150mg $400 2022-05-15 Buy
Cayman Chemical 15008 Exemestane ≥95% 107868-30-4 5mg $39 2023-01-06 Buy
Cayman Chemical 15008 Exemestane ≥95% 107868-30-4 10mg $61 2023-01-06 Buy
Sigma-Aldrich Y0001756 Exemestane for system suitability European Pharmacopoeia (EP) Reference Standard 107868-30-4 y0001756 $218 2023-01-07 Buy
Product number Packaging Price Buy
PHR1634 1g $112 Buy
1269050 150mg $400 Buy
15008 5mg $39 Buy
15008 10mg $61 Buy
Y0001756 y0001756 $218 Buy

Exemestane Chemical Properties,Uses,Production

Indications and Usage

Exemestane is an irreversible steroid aromatase inhibitor. Its structure is similar to that of aromatase’s natural substrate, androstenedione, and acts as a pseudosubstrate. Postmenopausal women’s estrogen is mainly converted from androgen (produced by the adrenal cortex) by aromatase in the surrounding tissue. This drug irreversibly binds with the active site on aromatase to deactivate it, thus dramatically lower estrogen levels in the blood circulation of postmenopausal women. By inhibiting aromatase to lower estrogen levels, it can be used to treat hormone-dependent breast cancer in postmenopausal women.
Exemestane is suitable for treating advanced breast cancer in naturally or artificially postmenopausal women that has not responded well to tamoxifen treatment. It is also suitable for treating estrogen and progesterone receptor positive postmenopausal advanced breast cancer, and it can also be used to treat metastasized breast cancer and as adjuvant therapy for early breast cancer.

Pharmacokinetics

This drug has no noticeable effect on adrenal corticosteroids biosynthesis. Even when its concentration is over 600 times the concentration required to inhibit aromatase, it still has no noticeable effect the other enzymes in the corticosteroid production pathway.
This drug is absorbed quickly when taken orally and will affect food absorption. Its oral bioavailability is 42%. Postmenopausal women have a higher absorption rate than healthy test subjects. Patients reach peak blood concentration 2-4 hours after intake, and the peak lasts for an average of 1.2 hours, which is 2.9 hours shorter than healthy subjects. It mainly binds to Α1-acid glycoprotein and protein, and its overall binding rate to protein is 90%. It is mainly metabolized by the liver, the metabolite is inactive 17-Hydrecoxetron, and its clearing half-life is 24 hours. It is mostly excreted through urine and feces, which both account for 42% of the consumed amount.

Drug interactions

1. This drug cannot be used in combination with estrogen-based drugs to avoid counteracting its medicinal effects.
2. Exemestane is mostly metabolized by CYP3A4, but when used in combination with a strong CYP3A4 inhibitor (Ketoconazole), its pharmacokinetics do not exhibit any change. This is because the inhibitor does not seem to affect the drug’s pharmacokinetics, but it is also possible that the known CYP3A4 inducer lowers the blood concentration of Exemestane.

Side effects

Adverse effects include nausea, dryness, constipation, diarrhea, dizziness, insomnia, rash, fatigue, fever, swelling, pain, vomiting, abdominal pain, increased appetite, weight gain, etc. Additionally, some literature reports cases of hypertension, depression, anxiety, difficulty breathing, coughing, etc. There may also be decreases lymph cell amounts, abnormalities in liver function indicators (such as alanine aminotransferase), etc.

Clinical Research

For patients resistant to tamoxifen, 25mg of Exemestane, qd, can achieve an objective efficacy rate of 15-28% and a median continuation period of 69-76 weeks. Exemestane is superior to Megestrol, and it can extend the disease progression time. For patients who have worsened conditions following Megestrol treatment, Exemestane can still achieve an objective efficacy rate of 11-13%. A daily 25mg dose of Exemestane has an objective efficacy rate of 6.6% on patients who have not responded to non-steroidal aromatase inhibitors, and the two drugs are not cross-resistant.

Contradictions

1. Not to be used by patients allergic to this drug.
2. Not to be used by pregnant women, breastfeeding women, and children.

Warnings and precautions

1. Premenopausal women usually do not use Exemestane.
2. Patients with moderate to severe liver or renal failure should use with caution. Exceeding the recommended dosage of Exemestane may increase the occurrence of nonfatal adverse effects.
3. FDA labeled this drug’s pregnancy safety as level D.
4. Elderly patients do not require any special precautions.

Description

Exemestane was launched in US and other countries for the treatment of estrogendependent tumors and postmenopausal breast cancer. It is a novel steroidal compound structurally related to the natural substrate for the biosynthesis of estrogen, androstanedione, and can be synthesized by methylidenation of androsta-1, 4-dien- 17beta-ol-3-one in 6 position then oxidation of the alcohol function. Exemestane is an irreversible inactivator of the aromatase enzyme system, so inducing in vivo a dose-related sustained suppression of serum estrogen and minimal endocrine activity. It is the first steroidal representative of the third-generation of orally active aromatase inhibitors with a highly potent and selective mechanism of action, displaying good tolerability and safety profile. In rats with DMBA-induced mammary tumors, 10 to 100 mglkg of exemestan administered po twice-daily for 4 weeks resulted in 76 to 88% regression. In women failing anti-estrogen therapy with tamoxifen, this agent has demonstrated high activity in locally advanced or metastatic disease. In addition, it may also have potential for breast cancer prevention.

Chemical Properties

white to light yellow crystal powder

Originator

Farmitalia Carlo Erba (Italy)

Uses

An antineoplastic (hormonal)

Uses

antiinfective

Uses

Labeled Exemestane, intended for use as an internal standard for the quantification of Exemestane by GC- or LC-mass spectrometry.

Definition

ChEBI: A 17-oxo steroid that is androsta-1,4-diene-3,17-dione in which the hydrogens at position 6 are replaced by a double bond to a methylene group. A selective inhibitor of the aromatase (oestrogen synthase) system, it is used in the treatment of advanced brea t cancer.

Manufacturing Process

0.50 g of 6-methylenandrost-4-ene-3,17-dione and 0.57 g of dichlorodicyanobenzoquinone were refluxed in 20 ml of anhydrous dioxane for about 15 hours. To remove the DDQ the suspension was filtered through alumina. After evaporation of the solvent the residue was dissolved in ethyl acetate, the organic layer washed with water, dried over sodium sulfate and the solvent removed under vacuum. The crude product was chromatographed on silica gel using hexane/ethyl acetate to yield 0.25 g of pure 6- methylenandrosta-1,4-diene-3,17-dione, m.p. 188-191°C, λmax 247 nm (ε 13.750).

brand name

Aromasin (Pharmacia& Upjohn).

Therapeutic Function

Antineoplastic

General Description

Exemestane, 6-methylenandrosta-1,4-diene-3,17-dione (Aromasin), is the first steroid-basedaromatase inhibitor approved for the treatment of breastcancer in the United States. It is a mechanism-based inactivatorthat irreversibly inhibits the enzyme. Plasma estrogenlevels are reduced by 85% to 95% within 2 to 3 days, and effectslast 4 to 5 days. Exemestane does not inhibit any of themajor cytochromes P450 and has essentially no interactionwith steroid receptors, with only a very weak affinity for theAR. The 17β-hydroxyexemestane reduction product, however,has much higher affinity for the AR than the parent(still several fold less than DHT, 0.28% for parent vs. 30%for metabolite). The clinical significance of the affinity islikely minimal because of the low levels of the metaboliteproduced.

Hazard

A reproductive hazard.

Biochem/physiol Actions

Exemestane is a steroidal antiestrogen and irreversible aromatase inhibitor. Exemestane acts as a false substrate for the aromatase enzyme. Exemestane also prevents the conversion of androgens to estrogens and is used to treat estrogen-dependent breast cancer.

Clinical Use

Irreversible, steroidal aromatase inhibitor:
Treatment of breast cancer

Drug interactions

Potentially hazardous interactions with other drugs
None known

Metabolism

Metabolised via oxidation by the cytochrome P450 isoenzyme CYP3A4, and via reduction by aldoketoreductase. Metabolites are excreted in the urine (39-45%) and faeces (36-48%).

References

[1] franco buzzetti, enrico di salle, antonio longo, gabriella briatico. synthesis and aromatase inhibition by potential metabolites of exemestane (6-methylenandrosta-1,4-diene-3,17-dione). steroids. november 1993. 58(11): 527-532.
[2] gustavo de albuquerque cavalcanti, bruno carius garrido, felipe dias leal, monica costa padilha, xavier de la torre, francisco radler de aquino neto. detection of new urinary exemestane metabolites by gas chromatography coupled to mass spectrometry. steroids. september–october 2011. 76(10-11): 1010-1015.
[3] stephanie a. jones, stephen e. jones. exemestane: a novel aromatase inactivator for breast cancer. clinical breast cancer. october 2000. 1(3): 211-216.

19457-55-7
107868-30-4
Synthesis of Exemestane from 6-METHYLENEANDROST-4-ENE-3,17-DIONE

Exemestane Suppliers

Global( 543)Suppliers
Supplier Tel Email Country ProdList Advantage
Shenzhen Monkono Technology Co.,Ltd
+86-17063441314 sansbiotech@outlook.com China 677 58
Shanghai Longyu Biotechnology Co., Ltd.
+8615821988213 info@longyupharma.com China 2511 58
Changzhou Xuanming Pharmaceutical Technology Co., Ltd.
+8618068519287 sales@xuanmingchem.com China 304 58
Zhejiang J&C Biological Technology Co.,Limited
+1-2135480471 +1-2135480471 sales@sarms4muscle.com China 3447 58
Wuhan Godbullraw Chemical Co.,ltd
+86-13387603994 emilysales@godbullraw.com China 93 58
Wuhan Godbullraw Chemical Co.,ltd
+86-18986015478 Amysales@godbullraw.com China 520 58
Hubei Lange Biotechnology Co., Ltd.
+8617762501948 sales2@langebiotech.com China 154 58
Henan Guange Biotechnology Co. LTD
+8613203739091 admin@guange-chem.com China 2195 58
Hebei Brisk New Material Technology Co. , Ltd.
+8613323042040 alice@brisknm.com China 209 58
Beijing Cooperate Pharmaceutical Co.,Ltd
010-60279497 sales01@cooperate-pharm.com CHINA 1811 55

Related articles

View Lastest Price from Exemestane manufacturers

Image Update time Product Price Min. Order Purity Supply Ability Manufacturer
Exemestane pictures 2023-03-29 Exemestane
107868-30-4
US $1.00-35.00 / g 1g 99% 100kg Wuhan Cell Pharmaceutical Co., Ltd
Exemestane pictures 2023-03-29 Exemestane
107868-30-4
US $9.90-3483.00 / KG 10g/Bag 99.99%HPLC.USP42——Powder、Oil、Pills、Capsules、Tablets,Customized packaging 100KG Wuhan Biocar Pharmacy Co., Ltd.
ExeMestane(AroMasin) pictures 2023-03-29 ExeMestane(AroMasin)
107868-30-4
US $4000.00 / kg 1kg 99.99% 2 tons Wuhan Cell Pharmaceutical Co., Ltd
  • Exemestane pictures
  • Exemestane
    107868-30-4
  • US $1.00-35.00 / g
  • 99%
  • Wuhan Cell Pharmaceutical Co., Ltd
  • Exemestane pictures
  • Exemestane
    107868-30-4
  • US $9.90-3483.00 / KG
  • 99.99%HPLC.USP42——Powder、Oil、Pills、Capsules、Tablets,Customized packaging
  • Wuhan Biocar Pharmacy Co., Ltd.

Exemestane Spectrum

ExeMestane (USP) ExeMestane(AroMasin) 1,4-Androstadien-3,17-dione-6-Methylene-d2 (8R,9S,10R,13S,14S)-10,13-Dimethyl-6-methylene-7,8,9,11,12,13,15,16-octahydro-6H-cyclopenta[a]phenanthrene-3,17(10H,14H)-dione ExeMestine (8R,9S,10R,13S,14S)-10,13-diMethyl-6-Methylene-7,8,9,10,11,12,13,14,15,16-decahydro-3H-cyclopenta[a]phenanthrene-3,17(6H)-dione ExeMestane SynonyMs 6-Methylenandrosta-1,4-diene-3,17-dione PNU155971 Exemestane for system suitability Exemestance:6-methyleneandrosta-1,4-diene-3,17-dione Exemestane D2 FCE24304;FCE-24304 Exemestane(FCE 24304) 10,13-dimethyl-6-methylene-7,8,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,17-dione Exemestane - Aromasin | FCE 24304 Exemestone EXE 6-methylenandrosta-1,4-diene-3,17-dione 6-METHYLENEANDROSTA-1,4-DIENE-3,17-DIONE Exemestan Exemestance 10,13-dimethyl-6-methylidene-7,8,9,10,11,12,13,14,15,16-decahydrocyclopenta[a]phenanthrene- EXEMESTANE FCE-24304 AROMASIN Androsta-1,4-diene-3,17-dione, 6-methylene EXALAMIDE Aromasin/exemestane Aromasin CAS 107868-30-4 6-Methyleneandrosta-1,4-diene-3,17-dione, FCE-24304, Aromasin Exemestane CRS Exemestane for system suitability CRS [2H2]-Exemestane Aromasin Exeme Acatate? Exemestane USP/EP/BP Steroids Raw Powder Hormone Exemestane, Aromasin Exemestane(USFDA/CEP) ROMASIN Exemestane (Aromasin,EXE)-1 gram(17) Exemestane 13C D2Q: What is Exemestane 13C D2 Q: What is the CAS Number of Exemestane 13C D2 Q: What is the storage condition of Exemestane 13C D2 Q: What are the applications of Exemestane 13C D2 Exemestane D2Q: What is Exemestane D2 Q: What is the CAS Number of Exemestane D2 Q: What is the storage condition of Exemestane D2 Q: What are the applications of Exemestane D2 Exemestane for system suitability (Y0001756) ExemestaneQ: What is Exemestane Q: What is the CAS Number of Exemestane Q: What is the storage condition of Exemestane Q: What are the applications of Exemestane Exemestane (1269050) Exemestane 107868-30-4 107868-30-4 156-1-31 7868-30-4 107968-30-4 C20H24O2 2964 Intermediates & Fine Chemicals Pharmaceuticals Steroids Pfizer compounds Steroid and Hormone API Inhibitors